BioSpace News Archive

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s filing to review a Biologic License Application (BLA) for its investigational treatment rozanolixizumab, and that the Agency has granted Priority Review.

January 6, 2023
·
18 min read
Genetown

METiS Announces License Agreement with Evopoint Biosciences

METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, announced they have entered a collaboration with Evopoint Biosciences Co., Ltd., a biopharmaceutical company focused on discovering and developing innovative and transformative medicines.

January 6, 2023
·
2 min read
Drug Development

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) recently announced additional results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy.

January 6, 2023
·
9 min read
Genetown

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference.

January 6, 2023
·
10 min read
Genetown

ASSAYQUANT TECHNOLOGIES, INC. TO PRESENT AT BIOTECH SHOWCASE™ 2023

AssayQuant Technologies, Inc announced today that it is presenting at Biotech Showcase™ 2023.

January 6, 2023
·
3 min read
Biotech Beach

Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete responses in a total of 6 relapsed/refractory AL amyloidosis patients.

January 6, 2023
·
7 min read
BioMidwest

HTG Announces Certain Preliminary 2022 Unaudited Financial Results

HTG Molecular Diagnostics, Inc. announced certain preliminary, unaudited financial results for the year ended December 31, 2022.

January 6, 2023
·
4 min read
BioMidwest

OrthoPediatrics Corp. Establishes Direct Sales Organization in Germany

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the establishment of its direct sales organization in Germany.

January 6, 2023
·
2 min read
Pharm Country

Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

KBP Biosciences PTE. Ltd. today announced that an overview of Ocedurenone (KBP-5074) as a potential new treatment option addressing the unmet medical need of patients with uncontrolled and resistant hypertension and advanced CKD was presented by Pablo Pergola MD, PhD.

January 6, 2023
·
7 min read
Genetown

CORIUM TO PRESENT AT 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Corium LLC (Corium) announced that President and Chief Executive Officer, Perry J. Sternberg will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:00 p.m. Pacific.

January 6, 2023
·
1 min read